NCT03162926View on ClinicalTrials.gov

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

February 15, 2018

Conditions
Type 1 Diabetes Mellitus
Interventions
COMBINATION_PRODUCT

VC-02 Combination Product (aka PEC-Direct)

PEC-01 cells loaded into a Delivery Device

Trial Locations (1)

Unknown

University of Alberta, Edmonton

Sponsors

Lead Sponsor

ViaCyte
All Listed Sponsors
lead

ViaCyte

INDUSTRY